Plain Language Summary {#S0001}
======================

Diabetic retinopathy (DR) is a vision-threatening complication of diabetes. It can range in severity from mild, moderate, or severe nonproliferative DR (NPDR) to proliferative DR (PDR; the most severe form of the disease). The most common cause of vision loss in DR is the development of fluid around the light-sensitive cells in the center of the retina (called diabetic macular edema \[DME\]). Effective treatments are available, but not all patients achieve the same level or speed of improvement following treatment with the same drug. The purpose of this study was to take a look back at the clinical trials that first demonstrated the efficacy of ranibizumab in eyes with DR and DME in order to determine which factors made it more likely that a patient would achieve a rapid, robust improvement in DR severity during treatment with ranibizumab. This study found that patients with the most robust early improvements in DR severity (by month 6) were more likely to have had moderately severe or severe NPDR or PDR at the start of treatment (rather than less severe DR) and had their DME disappear after just 3 months of treatment.

Introduction {#S0002}
============

Diabetic retinopathy (DR) is the leading cause of impaired vision among the working-age adult population in developed countries.[@CIT0001],[@CIT0002] It is an insidiously progressive disease that can worsen over time to proliferative DR (PDR) and can lead to vision-threatening complications such as diabetic macular edema (DME; the leading cause of vision loss in DR).[@CIT0002],[@CIT0003] The Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study showed that many patients diagnosed with DR continue to progress to vision loss despite diligent monitoring and control of blood glucose concentration.[@CIT0004]--[@CIT0006]

Vascular endothelial growth factor (VEGF) is one of the key factors mediating the underlying pathology of DR and DME.[@CIT0003],[@CIT0007]--[@CIT0009] Several clinical trials have shown that intravitreal injections of anti-VEGF agents reduce DR progression and produce clinically and statistically significant improvements in DR severity.[@CIT0010]--[@CIT0021] Among eyes with DR and DME treated with the anti-VEGF agent ranibizumab in the RIDE (NCT00473382) and RISE (NCT00473330) clinical trials, a significant percentage exhibited an at least 2- or 3-step improvement from baseline in DR severity as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS).[@CIT0012],[@CIT0021]-[@CIT0023] Approximately 20% and 4% achieved an at least 2- or 3-step improvement, respectively, by month 3, and the percentage of DR responders steadily increased with monthly treatment ([Figure 1](#F0001){ref-type="fig"}; reproduced with permission from Sun et al 2019).[@CIT0021] The proportion of eyes achieving a 2-step or greater DR improvement with ranibizumab was statistically significant compared with sham injections at all follow-up visits.[@CIT0020] This is clinically important because DR regression of 2 steps or more is accompanied by marked improvements in vision and is associated with a high rate of DME resolution in eyes with DME.[@CIT0024]Figure 1Bar graphs showing DR severity improvement with ranibizumab monthly therapy over the 36 months of the randomized phase of the RIDE/RISE trials (observed data pooled from both trials). The sham group received sham injections from baseline to month 24; patients then crossed over to ranibizumab 0.5 mg monthly from months 25--36. DR severity was assessed using the ETDRS-DRSS. Graph includes all patients, including those with no room for improvement due to low baseline ETDRS-DRSS scores. Reprinted from *Ophthalmology,* 126(5), Sun JK, Wang PW, Taylor S, Haskova Z. Durability of diabetic retinopathy improvement with as-needed ranibizumab: open-label extension of RIDE and RISE studies, 712--720, Copyright (2019), with permission from Elsevier.[@CIT0021]**Abbreviations:** DR, diabetic retinopathy; DRSS, Diabetic Retinopathy Severity Scale; ETDRS, Early Treatment Diabetic Retinopathy Study.

Understanding why some eyes experience early, clinically meaningful DR improvements with anti-VEGF agents could provide important insights for both health care providers and patients as to the best time to initiate anti-VEGF therapy, and could help ensure the best outcomes for individual patients (personalized approach). To date, the few studies that have investigated the predictors of DR improvement with anti-VEGF therapy have focused on outcomes after 12 and 24 months of treatment.[@CIT0011],[@CIT0020],[@CIT0025]

In this study, we investigated the clinical features and key baseline characteristics associated with early robust DR improvement during ranibizumab therapy in the RIDE/RISE clinical trials.

Methods {#S0003}
=======

The study design and methods for the RIDE/RISE clinical trials (NCT00473382/NCT00473330) have been published and are described briefly below.[@CIT0023]

RIDE/RISE were identical, Phase 3, prospective, multicenter, randomized, 36-month clinical trials. The studies adhered to the tenets of the Declaration of Helsinki and informed consent guidelines, and were in compliance with the regulations of the Health Insurance Portability and Accountability Act. The study protocols were prospectively approved by the institutional review board at each study site ([[Supplementary Table](https://www.dovepress.com/get_supplementary_file.php?f=247061.docx)]{.ul}).

Adults with type 1 or 2 diabetes were eligible for enrollment if they had decreased vision due to DME in at least 1 eye. Patients across all levels of DR severity were included in the trials, ranging from DR severity 10 (no DR) through 75 (high-risk PDR). Approximately one-third of the patients had mild or moderate nonproliferative DR (NPDR), one-third had moderately severe or severe NPDR, and one-third had PDR, mostly mild and moderate. Less than 3.5% of patients had high-risk PDR or questionable/no DR. Patients were excluded if they had unclear ocular media that would prevent capture of color fundus photographs or fluorescein angiograms. They were also excluded if they had any of the following interventions within 3 months of the screening visit: vitreoretinal surgery, panretinal photocoagulation (PRP) or macular laser, intraocular corticosteroids, or intravitreal antiangiogenic drugs. Patients with uncontrolled hypertension, uncontrolled diabetes, or recent (within 3 months) cerebrovascular accident or myocardial infarction were also excluded.

One eye per patient was designated as the study eye and randomized to monthly intravitreal ranibizumab (0.5 or 0.3 mg) or sham injections. All sham eyes crossed over to ranibizumab 0.5 mg at month 24. PRP was recommended in cases of high-risk PDR and permitted at the investigator's discretion in cases of severe NPDR or non--high-risk PDR.[@CIT0023]

Outcome Measures Relevant to the Present Analyses {#S0003-S2001}
-------------------------------------------------

Eyes with evaluable color fundus photographs were assessed at baseline, month 3, and month 6 for DR severity by masked professional graders at an independent reading center (Fundus Photograph Reading Center at the University of Wisconsin, Madison, WI) using the ETDRS-DRSS, a validated standardized scale originally developed and published by the ETDRS Research Group in 1991 and later adopted for use in assessments of DR severity changes in clinical trials.[@CIT0012] The scale includes the following grades: DRSS 10, 12 (DR absent), DRSS 14, 15, 20 (DR questionable), DRSS 35 (mild NPDR), DRSS 43 (moderate NPDR), DRSS 47 (moderately severe NPDR), DRSS 53 (severe NPDR), DRSS 61 (mild PDR), DRSS 65 (moderate PDR), DRSS 71 and 75 (high-risk PDR), DRSS 81 and 85 (advanced PDR). The scale is not linear and was originally designed to provide a tool to measure DR worsening and the associated increasing risk of vision loss. Therefore, the magnitude of change between individual steps on the scale qualitatively differ, even though they are assessed the same way when measured in a quantitative, numerical step-change manner. The presence or absence of DME (defined as central subfield thickness \>250 µm on time-domain optical coherence tomography) was also assessed at month 3.

The proportion of eyes with an at least 2- or 3-step DR improvement on the ETDRS-DRSS from baseline to months 3 and 6 was assessed. Only eyes with room to improve were included in these analyses; a mild DRSS of at least 35 that improves by 2 steps (ie, to level 15) improves to 'DR questionable' status, while a moderate DRSS of at least 43 that improves by 2 steps (ie, to level 20) is still considered as having DR. Therefore, only eyes with a DRSS score of at least 43 underwent the 3-step evaluation. The number of eyes assessed for 2-step or greater DR improvement was 394 and 372 at months 3 and 6, respectively. The number of eyes assessed for 3-step or greater DR improvement was 328 and 308 at months 3 and 6, respectively.

Data Analyses and Statistics {#S0003-S2002}
----------------------------

Univariate analyses using Student's *t*-tests and chi-square tests were used to determine which baseline or early response characteristics were associated with 2-step or greater DR improvement in ranibizumab-treated patients. Characteristics evaluated included demographics, medical history, and systemic therapy, as well as ocular and systemic disease characteristics ([Table 1](#T0001){ref-type="table"}). Note that a history of PRP was not included in the multivariable analysis of potential predictors because the presence of PRP scars automatically rendered a DR severity score of ≥60 and prevented these eyes from being graded with a score \<60, even if there was an improvement in the retina surrounding the scars. Multivariable analyses were performed using logistic regression with backward selection, and included variables significant at the 0.05 significance level in the univariate analyses.Table 1Characteristics Assessed in Univariate Analyses for Association with Improvements in DR at Months 3 and 6CategoryCharacteristicsDemographicsAgeSexRaceEthnicityMedical historyDiabetes durationHbA1cHistory of hypertensionHypertension durationHistory of hypercholesterolemia/hyperlipidemiaHypercholesterolemia/hyperlipidemia durationBMI (\<30, ≥30 kg/m^2^)Systemic therapyDiabetes medications (insulin alone, insulin plus other, other alone, no diabetes medication)Cholesterol medicationsHypertension medicationsThiazolidine medicationsOcular characteristicsBaseline lens statusDR severity at baseline (35/43, 47/53, 60--75)Months since DR or DME diagnosisBaseline BCVA (≤35, 35--50, \>50 ETDRS letters)Baseline central foveal thickness on TD-OCT (≤400, \>400 μm)Baseline macular nonperfusionDME status at month 3[^1]

Analyses were completed with observed data for all variables. The ranibizumab 0.3 and 0.5 mg treatment arms were pooled for analysis. Analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC).

Results {#S0004}
=======

Patient Population {#S0004-S2001}
------------------

A total of 502 eyes were randomized to treatment with ranibizumab 0.3 or 0.5 mg in the RIDE/RISE trials.[@CIT0023] Of these, 460 eyes had evaluable color fundus photographs at baseline.

Demographic characteristics at baseline for the eyes that were evaluated in the current analysis are shown in [Table 2](#T0002){ref-type="table"}. The distribution of DR severities at baseline are shown in [Table 3](#T0003){ref-type="table"}. DR severity scores at baseline ranged from 35 to 75. A small proportion of patients with DR absent (0.5%; DRSS 10, 12) or questionable (1.3%; DRSS 14, 15, 20) were not included in the analyses due to lack of room for improvement. At baseline, 66.5% of patients had NPDR (DRSS \<60) and 33.5% had PDR (DRSS ≥60). Approximately 27% of the overall population had prior PRP.Table 2Baseline Characteristics of Analysis Cohort (Ranibizumab 0.3/0.5 mg--Treated Patients Only, Limited to DR Severity ≥35)Evaluable Eyes (N=460)Age, years, mean (SD)61.8 (10.1)Sex, male, n (%)268 (58.3)Race, n (%) White367 (82.1)\* Black or African American50 (11.2)\* Asian23 (5.1)\* Native Hawaiian or other Pacific Islander4 (0.9) American Indian or Alaska Native3 (0.7)Ethnicity, n (%) Hispanic or Latino101 (22.4)\* Not Hispanic or Latino350 (77.6)\*Body mass index, n (%) \<30 kg/m^2^203 (45.1)\* ≥30 kg/m^2^247 (54.9)\* Duration of diabetes, years, mean (SD)15.7 (9.4) HbA1C, mean (SD)7.7 (1.4) Baseline BCVA, letters, mean (SD)56.7 (11.9) Baseline CFT, µm, mean (SD)471.0 (158.3)Baseline DR severity category, n (%) 35/43144 (31.3) 47/53162 (35.2) 60--75154 (33.5)[^2] Table 3DR Severity at BaselineBaseline DR Severity (ETDRS-DRSS), n (%)Evaluable Eyes (N=460)Mild or moderate NPDR 3581 (17.6) 4363 (13.7)Moderately severe or severe NPDR 47138 (30.0) 5324 (5.2)PDR 60/61133 (28.9) 6516 (3.5) 714 (0.9) 751 (0.2)[^3]

The proportion of eyes in the pooled ranibizumab treatment groups with an at least 2- or 3-step improvement from baseline in ETDRS-DRSS at months 3 and 6 is shown in [Figure 2](#F0002){ref-type="fig"}. Note that a 2-step or greater DR improvement occurred in one-fifth of eyes at month 3 and in nearly one-third at month 6.Figure 2Bar graph showing early responders. Proportion of eyes treated with ranibizumab (0.3 and 0.5 mg arms pooled) with an at least 2- or 3-step DR improvement from baseline at 3 and 6 months. DR severity was assessed using the ETDRS-DRSS. Only eyes with room to improve on the ETDRS-DRSS were included in this analysis.**Abbreviations:** DR, diabetic retinopathy; DRSS, Diabetic Retinopathy Severity Scale; ETDRS, Early Treatment Diabetic Retinopathy Study.

The characteristics significantly associated (*P*\<0.05) with an at least 2- or 3-step DR improvement from baseline to months 3 and/or 6 in the univariate analyses are shown in [Table 4](#T0004){ref-type="table"}. When factors significantly associated with a 2-step or greater DR improvement were evaluated using multivariable analysis, only baseline DR score was found to be predictive of a 2-step or greater improvement at both months 3 and 6 ([Figure 3](#F0003){ref-type="fig"}). At month 3, there were significantly (*P*\<0.0001) greater odds of 2-step or greater improvement in eyes with moderately severe to severe NPDR compared with eyes with mild to moderate NPDR (odds ratio \[OR\], 24.4; 95% confidence interval \[CI\], 7.4--83.3) or PDR (OR, 3.3; 95% CI, 1.9--5.9; [Figure 3A](#F0003){ref-type="fig"}). Similarly, at month 6, a 2-step or greater improvement was significantly (*P*\<0.0001) more likely in eyes with moderately severe to severe NPDR than in eyes with mild to moderate NPDR (OR, 28.6; 95% CI, 12.7--66.7) or PDR (OR, 15.4; 95% CI, 8.0--29.4). The absence of DME at month 3 was also predictive of a 2-step or greater DR improvement at month 6 (*P*=0.008); the OR (95% CI) was 2.2 (1.2--3.9) for DME absent versus DME present ([Figure 3B](#F0003){ref-type="fig"}).Table 4Characteristics Associated with Improvements in DR at Months 3 and 6 in the Univariate Analysis (*P*\<0.05)Month 3Month 62-Step or Greater ImprovementAge (*P*=0.042)Duration of diabetes (*P*=0.046)Duration of hypertension (*P*=0.005)Baseline DR severity (*P*\<0.0001)Months since DR or DME diagnosis (*P*=0.040)Macular nonperfusion (*P*=0.001)Age (*P*=0.017)Duration of diabetes (*P*=0.003)Baseline DR severity (*P*\<0.0001)Months since DR or DME diagnosis (*P*=0.001)DME at month 3 (*P*=0.002)3-Step or Greater ImprovementBlack race (*P*=0.003)Baseline DR severity (*P*=0.011)Age (*P*=0.041)Baseline DR severity (*P*=0.040)Baseline BCVA (*P*=0.010)Macular nonperfusion (*P*=0.038)[^4] Figure 3Forest plots showing factors predictive of early 2-step or greater DR improvement (multivariable analysis) at (**A**) month 3 and (**B**) month 6.**Abbreviations:** CI, confidence interval; DME, diabetic macular edema; DR, diabetic retinopathy; NPDR, nonproliferative diabetic retinopathy; OR, odds ratio; PDR, proliferative diabetic retinopathy.

Among eyes with a 2-step or greater DR improvement (79 eyes at month 3; 116 eyes at month 6), the majority had moderately severe to severe NPDR at baseline ([Figure 4A](#F0004){ref-type="fig"}). Among eyes with a 3-step or greater DR improvement (12 eyes at month 3; 18 eyes at month 6), the majority had PDR at baseline ([Figure 4B](#F0004){ref-type="fig"}).Figure 4Bar graphs showing the distribution of baseline DR severity among early responders with (**A**) 2-step or greater or (**B**) 3-step or greater DR improvement. DR severity assessed using the Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale.**Abbreviations:** DR, diabetic retinopathy; NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.

Among eyes with a 2-step or greater DR improvement at month 6, 61.9% had experienced resolution of DME at month 3 ([Figure 5](#F0005){ref-type="fig"}). A 2-step or greater DR improvement at month 6 was seen in 38.7% (70/181) of eyes that had resolution of DME at month 3, but in only 23.5% (43/183) of eyes that had persistent DME at month 3. Among eyes with persistent DME at month 3, 70.9% (139/196) still had DME at month 6.Figure 5Bar graph showing the distribution of DME status at month 3 among eyes with or without a 2-step or greater improvement from baseline in DR at month 6. DR severity assessed using the Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale.**Abbreviations:** DR, diabetic retinopathy; DME, diabetic macular edema.

Discussion {#S0005}
==========

This study determined that the key predictive factor associated with early (month 3 and 6) robust DR regression in ranibizumab-treated eyes in the RIDE/RISE clinical trials was baseline DR severity score. The majority of eyes that experienced an early 2-step or greater DR improvement with ranibizumab at these timepoints had moderately severe to severe NPDR at baseline, and the majority of eyes with an early 3-step or greater DR improvement had PDR at baseline. Moreover, resolution of DME at month 3 was also predictive of a 2-step or greater DR improvement at month 6, consistent with an earlier finding that improvements in DME and DR during ranibizumab treatment are correlated.[@CIT0024]

Our findings regarding the effect of baseline DR severity on the response to ranibizumab treatment are consistent with the results of other analyses of the RIDE/RISE trials that focused on later timepoints. Dhoot et al evaluated characteristics predictive of clinically meaningful DR improvements after 12 and 24 months of treatment with ranibizumab in RIDE/RISE and found that baseline DR severity was predictive of 2-step or greater DR improvement at both months 12 and 24.[@CIT0025] Wykoff et al[@CIT0020] also evaluated the long-term outcomes from RIDE/RISE and found that the highest rate of 2-step or greater DR improvement at month 24 occurred in eyes with moderately severe to severe NPDR at baseline (78.4% in the ranibizumab 0.3 mg group and 81.1% in the ranibizumab 0.5 mg group). These improvements were seen as early as month 3 in approximately one-third of eyes with moderately severe to severe NPDR at baseline.[@CIT0020] Our new predictive analyses of early improvements, taken together with the past long-term results, suggest that it may be most beneficial to initiate anti-VEGF therapy in eyes with DR as soon as the condition has progressed to moderately severe or severe NPDR to ensure the greatest likelihood of both early and long-term robust improvements in DR. The present results also demonstrate, however, that eyes with PDR can still experience clinically meaningful improvements in DR severity with ranibizumab and should therefore also be considered for prompt treatment.

The present analysis also found that a 2-step or greater DR improvement at month 6 was more common among eyes with DME resolution by month 3 than in those who still had DME at month 3. Corresponding data, consistent with the results of our new predictive analysis, were reported by Ip et al,[@CIT0024] who found that resolution of DME and significant improvement in best-corrected visual acuity (BCVA) is more common in eyes with an at least 2- or 3-step DR improvement at month 24. In fact, additional analyses on RIDE/RISE data demonstrated that among eyes that had both resolution of DME and a 2-step or greater DR improvement at month 3, only 17.5% experienced an additional 2-step or greater DR improvement between months 3 and 24 (unpublished data). This is expected because most of these eyes had improved to the point that they no longer had room to improve by an additional 2 or more steps in DR severity. These data are in accord with and supportive of the RIDE/RISE analyses published by Ip et al,[@CIT0024] which show that DR step improvements in patients with DME correlate with BCVA letter improvements, indicating the clinical importance of DR severity regression. Together, these findings show that there is a correlation between DME and DR responses to ranibizumab; this is consistent with the fact that both are associated with a VEGF-driven pathophysiology and that DME occurs as a complication of DR. Based on the existing data, we hypothesize that eyes that have early resolution of DME accompanied by early improvements in DR could be potentially good candidates for less frequent (less-than-monthly) ranibizumab treatment, while some eyes that do not have early resolution of DR and DME may benefit from continued treatment with anti-VEGF therapy for up to 12--18 months (when the plateau of the population response is reached; [Figure 1](#F0001){ref-type="fig"}).

To the best of our knowledge, this is the first study to investigate the clinical features and key baseline characteristics associated with early robust DR regression with ranibizumab therapy. This analysis was made possible because the RIDE/RISE trials enrolled patients with a wide range of DR severities and collected high-quality color fundus photographs after as few as three or six monthly injections. Until recently, most studies of anti-VEGF therapy in eyes with DR only collected fundus photographs at annual intervals. This was likely due to the perception of DR as a disease that would be unlikely to either progress or resolve during a shorter time period.

Another strength of this study was that DR outcomes were graded by two well-trained professional masked graders at a central reading center using the ETDRS-DRSS (a well-validated standardized method), with one senior grader serving as an arbitrator in cases of disagreement.

The key limitation of this study is that the patient population in the RIDE/RISE trials may not be directly representative of patients in the typical real-world clinical practice setting. The eligibility criteria required all enrolled patients to have decreased vision from DME in at least one eye, and excluded patients with conditions that could interfere with the collection or interpretation of the study results (eg, unclear ocular media, prior vitreoretinal surgery, recent history of PRP or macular laser). Patients were also required to have well-controlled diabetes (glycated hemoglobin \>12%),[@CIT0023] which limited the ability to evaluate the relationship between glycated hemoglobin and early DR outcomes. Finally, the ETDRS-DRSS used for the evaluations of DR improvements in our analyses has limitations. The scale was not designed to assess DR improvements. It was originally designed to measure progressive DR worsening with associated increasing risk of vision loss. The scale is not linear and the individual DRSS steps differ in qualitative magnitude despite being assessed as the same quantitative difference. Inclusion of both qualitatively different disease states, NPDR and PDR, on the same linear scale could also be viewed as a limitation, especially when used for estimation of severity improvement in the absence of additional data, for example, extent of retinal ischemia.

In conclusion, the present study demonstrates that patients with the highest risk of DR progression (moderately severe/severe NPDR) and with the highest risk of vision-threatening complications (PDR) can achieve robust and rapid DR regression with ranibizumab treatment within the first few months of anti-VEGF treatment initiation. Interestingly, the majority of patients with the greatest magnitude of prompt 3-step or greater improvement at months 3 and 6 had PDR at baseline. These results highlight that it may not be too late for a pharmacological approach once eyes reach PDR, and eyes with PDR can have prompt and robust benefits with anti-VEGF treatment. These rapid and clinically meaningful DR improvements with ranibizumab were more likely to occur in those eyes that also experienced early resolution of DME. The data highlight the importance of a personalized treatment approach in patients with diabetic eye disease, supporting previous findings that eyes that achieved the most benefit from anti-VEGF treatment were those with moderately severe to severe NPDR.[@CIT0020] Further investigations of optimal treatment frequency to maintain these robust and rapid improvements, including more durable treatments and sustained delivery options for treatment of DR, are warranted.
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[^1]: **Abbreviations:** BCVA, best-corrected visual acuity; BMI, body mass index; DME, diabetic macular edema; DR, diabetic retinopathy; ETDRS, Early Treatment Diabetic Retinopathy Study; HbA1c, glycated hemoglobin; TD-OCT, time-domain optical coherence tomography.

[^2]: **Note:** \*Due to missing data, the denominator is smaller than the analysis cohort for some variables.

    **Abbreviations:** BCVA, best-corrected visual acuity; CST, central foveal thickness; DR, diabetic retinopathy; HbA1c, glycated hemoglobin.

[^3]: **Abbreviations:** DR, diabetic retinopathy; DRSS, Diabetic Retinopathy Severity Scale; ETDRS, Early Treatment Diabetic Retinopathy Study; NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.

[^4]: **Abbreviations:** BCVA, best-corrected visual acuity; DME, diabetic macular edema; DR, diabetic retinopathy.
